Assess the Role of the New COVID-19 MAb, Bebtelovimab
Bebtelovimab will expand monoclonal antibody (MAb) options for high-risk patients with mild to moderate COVID-19.
The Omicron variant limits OUTpatient MAb treatment options to sotrovimab. Now bebtelovimab is another choice for COVID-19 patients who are at high risk of severe illness (diabetes, etc).
Similar to sotrovimab, bebtelovimab is for adults...or kids age 12 and up who weigh 40 kg or more...and is provided at no cost.